Online inquiry

IVTScrip™ pT7-VEE-mRNA-Anti-TNFRSF4, ABBV-368 Vector   (CAT#: GTVCR-WQ171MR)

This product GTVCR-WQ171MR is an effective transcription system suitable for a variety of research, including the in vitro translation, self-amplifying mRNA studies and protein expression. The system was driven by the T7 promoter to efficiently generate mRNA ecoding antibody which targeting TNFRSF4. The vector contains the self-replicating Venezuelan equine encephalitis (VEE) virus RNA replicon, which resulting the mRNA expression at a high level.

SPECIFIC INQUIRY

3' poly(A):
Inquiry
Specifications
Product type Vector
Promoter T7
Resistance Ampicillin
Species Chimeric
RefSeq NM_003327.4
Applications IVT; Self-amplifying mRNA (SAM) research; Gene therapy research
Format Solution
Concentration 1 µg/µl
Quantity 10 µg
Target Gene
Gene ID 7293
UniProt ID P43489
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ pT7-VEE-mRNA-Anti-TNFRSF4, ABBV-368 Vector (GTVCR-WQ171MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTVCR-WQ1202MR IVTScrip™ pSP6-VEE-mRNA-Anti-CTGF, FG-3019 Vector Vector FG-3019
GTVCR-WQ1023MR IVTScrip™ pT7-VEE-mRNA-Anti-IL23A, CNTO-1959 Vector Vector CNTO-1959
GTVCR-WQ762MR IVTScrip™ pSP6-VEE-mRNA-Anti-CXCL10, BMS-936557 Vector Vector BMS-936557
GTVCR-WQ1710MR IVTScrip™ pSP6-VEE-mRNA-Anti-ITGA4&ITGB7, LDP-02 Vector Vector LDP-02
GTVCR-WQ2174MR IVTScrip™ pSP6-VEE-mRNA-Anti-TNF, PEG sTNF-RI Vector Vector PEG sTNF-RI
GTVCR-WQ1600MR IVTScrip™ pT7-VEE-mRNA-Anti-TNFRSF17, J6M0 Vector Vector J6M0
GTVCR-WQ883MR IVTScrip™ pT7-VEE-mRNA-Anti-S, CB-6 Vector Vector CB-6
GTVCR-WQ657MR IVTScrip™ pSP6-VEE-mRNA-Anti-PDCD1, BCD-100 Vector Vector BCD-100
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW